Join
Live feed
·
PRReleasevia Quantisnow
Myovant Sciences Ltd. logo
Urovant Sciences Ltd. logo

Urovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mg

ByQuantisnow·Wall Street's wire, on your screen.
MYOV· Myovant Sciences Ltd.UROV· Urovant Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MYOV (Myovant Sciences Ltd.), UROV (Urovant Sciences Ltd.) and more on Quantisnow.